Company: INDP
Filing Date: 2025-02-05
Form Type: S-3
Source: 0001493152-25-005016
Chunk: 12

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-02-05
Form: S-3
Chunk 12
---
 therein and any free
writing prospectuses that we have authorized for use in this offering with the understanding that our actual results or events could
differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. The forward-looking
statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking
statements, whether as a result of new information, future events or otherwise, except as required by law.

<div align='center'>USE OF PROCEEDS</div>

All of the shares of common stock offered by the selling stockholders pursuant to this prospectus will be sold by the selling stockholders for their respective accounts. We will not receive any of the proceeds from these sales.

We may receive proceeds from the exercise of the warrants to the extent that these warrants are exercised for cash. Warrants, however, are exercisable on a cashless basis. If all of the warrants were exercised for cash in full, the proceeds would be approximately $2.2 million. We currently intend to use the net proceeds of such warrant exercise, if any, to fund our research and development activities and for working capital and general corporate purposes.

We can make no assurances that any of the warrants will be exercised, or if exercised, that they will be exercised for cash, the quantity which will be exercised or in the period in which they will be exercised.

| 6 |

<div align='center'>DIVIDEND POLICY</div>

We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and future earnings, if any, for use in our business and therefore do not anticipate paying cash dividends in the foreseeable future. Payment of future dividends, if any, will be at the discretion of our board of directors after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs and other factors our board of directors deems relevant.

| 7 |

<div align='center'>SELLING STOCKHOLDER S</div>

The shares of common stock being offered by the selling stockholders are those shares of common stock issued in the January 2025 Private Placement as well as those issuable upon exercise of warrants issued in the January 2025 Private Placement. The following table sets forth the number and percentage of shares of our common stock beneficially owned by the selling stockholders as of February 4, 2024, taking into account number of shares that may be offered under this prospectus